These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21035151)

  • 1. [Chemotherapy and targeted treatments in glioblastomas].
    Chinot O; Soulier P; Frenay M
    Neurochirurgie; 2010 Dec; 56(6):491-8. PubMed ID: 21035151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of antiangiogenic therapies for glioblastomas.
    Arrillaga-Romany I; Reardon DA; Wen PY
    Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
    Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
    Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab for the treatment of glioblastoma.
    Chowdhary S; Chamberlain M
    Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What have we learned from trials on antiangiogenic agents in glioblastoma?
    Soffietti R; Trevisan E; Rudà R
    Expert Rev Neurother; 2014 Jan; 14(1):1-3. PubMed ID: 24417499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New molecularly targeted therapies for glioblastoma multiforme.
    Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
    Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options in recurrent glioblastoma--An update.
    Seystahl K; Wick W; Weller M
    Crit Rev Oncol Hematol; 2016 Mar; 99():389-408. PubMed ID: 26830009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of antiangiogenic treatment in glioblastoma.
    Chinot OL; Reardon DA
    Curr Opin Neurol; 2014 Dec; 27(6):675-82. PubMed ID: 25313693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of glioblastoma in the elderly.
    Sahebjam S; McNamara M; Mason WP
    Clin Adv Hematol Oncol; 2012 Jun; 10(6):379-86. PubMed ID: 22895239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.
    Wiewrodt D; Nagel G; Dreimüller N; Hundsberger T; Perneczky A; Kaina B
    Int J Cancer; 2008 Mar; 122(6):1391-9. PubMed ID: 18000822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of integrins in glioma biology and anti-glioma therapies.
    Tabatabai G; Tonn JC; Stupp R; Weller M
    Curr Pharm Des; 2011; 17(23):2402-10. PubMed ID: 21827415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy for glioblastoma: current status and future prospects.
    Batchelor TT; Reardon DA; de Groot JF; Wick W; Weller M
    Clin Cancer Res; 2014 Nov; 20(22):5612-9. PubMed ID: 25398844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic agents for the treatment of glioblastoma.
    Gerstner ER; Duda DG; di Tomaso E; Sorensen G; Jain RK; Batchelor TT
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1895-908. PubMed ID: 18041999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.